Evaluation of clinical trials done for orphan drugs versus nonorphan drugs in infectious diseasesan eleven year analysis [2010-2020]

BACKGROUND: The 1983 US Orphan Drug Act provided impetus for the development of new therapies for rare diseases. Several studies focused on the number of orphan designations over time. However, very few focused on clinical trials that lead to their approval, particularly for infectious diseases. MAT...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudyar, Palvi, Konwar, Mahanjit, Khatri, Zoya, Gogtay, Nithya Jaideep, Thatte, Urmila Mukund
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267988/
https://www.ncbi.nlm.nih.gov/pubmed/37325577
http://dx.doi.org/10.4103/picr.picr_137_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267988/
https://www.ncbi.nlm.nih.gov/pubmed/37325577
http://dx.doi.org/10.4103/picr.picr_137_21

Ejemplares similares